Rhode Island 2023 Regular Session

Rhode Island Senate Bill S0292 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3
4	4
5	5	2023 -- S 0292
6	6	========
7	7	LC001383
8	8	========
9	9	S TATE OF RHODE IS LAND
10	10	IN GENERAL ASSEMBLY
11	11	JANUARY SESSION, A.D. 2023
12	12	____________
13	13
14	14	A N A C T
15	15	RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACIES
16	16	Introduced By: Senators Valverde, Sosnowski, Lawson, Murray, Lauria, DiMario,
17	17	Miller, and Mack
18	18	Date Introduced: February 16, 2023
19	19	Referred To: Senate Health & Human Services
20	20
21	21
22	22	It is enacted by the General Assembly as follows:
23	23	SECTION 1. Chapter 5-19.1 of the General Laws entitled "Pharmacies" is hereby amended 1
24	24	by adding thereto the following section: 2
25	25	5-19.1-36. Tobacco cessation therapy prescriptive authority. 3
26	26	(a) A pharmacist who is licensed pursuant to this chapter and who meets the requirements 4
27	27	of this section may prescribe and dispense FDA-approved tobacco cessation drug therapies to a 5
28	28	qualified patient pursuant to rules and regulations adopted by the board of pharmacy, subject to the 6
29	29	approval of the director of health in consultation with the director of behavioral healthcare, 7
30	30	developmental disabilities and hospitals. 8
31	31	(b) For the purposes of this section, "qualified patient" means a patient who: 9
32	32	(1) Is at least eighteen (18) years of age; or of minimum age based on the most recent 10
33	33	guidance provided by the FDA; 11
34	34	(2) Is willing to participate in a structured tobacco cessation program consisting of an initial 12
35	35	evaluation and appropriate follow-up visits with the pharmacist prescribing tobacco cessation 13
36	36	products; and 14
37	37	(3) Has been educated on symptoms of nicotine toxicity, common and/or severe adverse 15
38	38	effects of prescribed medication(s), and when to seek medical treatment. 16
39	39	(c) Prior to prescribing tobacco cessation products, the pharmacist shall successfully 17
40	40	complete education on tobacco cessation therapy taught by a provider accredited by the 18
41	41	Accreditation Council for Pharmacy Education or by a comparable provider recognized by the 19
42	42
43	43
44	44	LC001383 - Page 2 of 3
45	45	Board of Pharmacy. 1
46	46	(d) The pharmacist shall refer or consult prior to prescribing regarding high-risk patients 2
47	47	or patients with an identified contraindication to FDA-approved tobacco cessation drug therapies 3
48	48	to the patient's primary care provider, as applicable, or to another provider, as appropriate. 4
49	49	(e) All pharmacists participating in prescribing therapy for tobacco cessation shall follow 5
50	50	the most updated guidelines and standards of care as approved by the board of pharmacy, subject 6
51	51	to the approval subject to the approval of the director of health in consultation with the director of 7
52	52	behavioral healthcare, developmental disabilities and hospitals. 8
53	53	(1) Pharmacists will implement the most updated clinical practice guidelines to help 9
54	54	patients quit using all forms of tobacco. 10
55	55	(2) Pharmacists' services will include an educational component to include counseling on 11
56	56	medication therapies and cessation strategies as well as referral to sources provided by the Rhode 12
57	57	Island department of health. 13
58	58	(f) Notification of the patient screening, the prescription record and the follow-up care plan 14
59	59	shall be provided to the patient's primary care provider, as applicable, within five (5) business days 15
60	60	following the prescribing of a tobacco cessation product. 16
61	61	(g) The definition of a qualified patient is subject to adaptation pursuant to rules and 17
62	62	regulations adopted by the board of pharmacy, subject to the approval of the director of health in 18
63	63	consultation with the director of behavioral healthcare, developmental disabilities and hospitals. 19
64	64	SECTION 2. This act shall take effect upon passage. 20
65	65	========
66	66	LC001383
67	67	========
68	68
69	69
70	70	LC001383 - Page 3 of 3
71	71	EXPLANATION
72	72	BY THE LEGISLATIVE COUNCIL
73	73	OF
74	74	A N A C T
75	75	RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACIES
76	76	***
77	77	This act would add a new section which sets forth conditions for pharmacists to prescribe 1
78	78	tobacco cessation drug therapies. 2
79	79	This act would take effect upon passage. 3
80	80	========
81	81	LC001383
82	82	========
83	83